Solicitor’s Views Requested By Supreme Court In Patent, Antitrust Case

(June 6, 2016, 12:34 PM EDT) -- WASHINGTON, D.C. — In its June 6 orders list, the U.S. Supreme Court invited the U.S. solicitor general to weigh in on a patent and antitrust dispute involving the epilepsy drug Lamictal (SmithKline Beecham Corp., et al. v. King Drug Company of Florence Inc., No. 15-1055, U.S. Sup.).

Question Presented

According to SmithKline Beecham Corp., d/b/a GlaxoSmithKline, and co-petitioner Teva Pharmaceuticals USA, the Third Circuit U.S. Court of Appeals erred in vacating and remanding findings by a New Jersey federal judge that a settlement of patent...
To view the full article, register now.